Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this systematic review, dutasteride may be more effective than finasteride for hair growth in men with androgenetic alopecia, but the comparative magnitude of this effect is highly uncertain.

In this retrospective, population-based cohort study, researchers found no significant difference in age-related macular degeneration incidence between BPH patients using 5α-reductase inhibitors and those on tamsulosin, but observed a slight increased risk with dutasteride compared to finasteride.

Finasteride and dutasteride have little effect on Type 2 Diabetes risk.

This study concluded that 5α-reductase inhibitors were linked to increased sexual dysfunction in men with benign prostatic hyperplasia, but not in men with androgenetic alopecia.

This review discusses various treatments for benign prostatic hyperplasia, comparing medications like finasteride and terazosin, as well as surgical and placebo options, without presenting new clinical findings.

Dutasteride and finasteride don't raise erectile dysfunction risk.

In this study, researchers investigated genetic variants in pharmacogenes affecting tadalafil and finasteride pharmacokinetics, finding fed volunteers had higher drug exposure than fasting individuals, but genetic variation did not significantly impact pharmacokinetics after correcting for multiple comparisons.

This study found that the proposed LC-MS/MS method accurately quantified the drug content in split tablets of finasteride and terbinafine, revealing significant variability and suggesting that non-scored tablets should not be split.

In this study, researchers developed a reliable HPLC method to simultaneously estimate Finasteride and Tadalafil in marketed formulations, showing precise, linear results with confirmed degradation susceptibility under certain stress conditions.

In this study, the release rate of Finasteride from Eudragit matrix tablets was found to be significantly influenced by the drug/Eudragit ratio and polymer viscosity, with formulation F9 being the most effective.

This study found that domestic finasteride tablets are bioequivalent to reference tablets, showing similar pharmacokinetic parameters and relative bioavailability.

This study concluded that the market for 5α-reductase inhibitors, including finasteride, epristeride, and dutasteride, is expected to grow with promising prospects.

Finasteride helps hair growth and prostate issues but may cause sexual side effects and increase tumor risk.

Tailored treatment is crucial for elderly men with BPH due to potential risks and benefits of medications.

Using data from the FDA's adverse event reporting system, this study identified 59 drugs linked to reduced male semen quality, with finasteride, dutasteride, and tamsulosin among the most frequently reported.

In a randomized study, men treated with dutasteride for androgenetic alopecia experienced sexual adverse events at twice the rate of those on placebo during 24 weeks, but these events were mild, moderate, and resolved after treatment.

This study reports the discovery of LX-38, a new high-affinity non-steroidal antagonist that could provide the therapeutic benefits of current BPH and AGA treatments without the hormonal side effects, utilizing a distinct "Orthogonal T-Stacking" scaffold for binding.

This study explored the effects of MOTILIPERM on infertility in a rat model with varicocele and oxidative stress, reporting its potential therapeutic efficacy.

Finasteride causes fewer sexual side effects than dutasteride in men with BPH.

Finasteride can cause sexual side effects like decreased libido and erectile dysfunction.

This study found that independent pharmacies in the St. Louis area offer significantly lower prices for tamsulosin and oxybutynin ER compared to chain pharmacies, while zip-code and median income show no pricing correlation.

This study concluded that domestic and imported finasteride tablets are bioequivalent, showing no significant differences in pharmacokinetic parameters among healthy volunteers.

This review discusses 5-alpha reductase inhibitors, highlighting their long-term efficacy and tolerability in treating benign prostate hyperplasia, while also noting sexual dysfunction as a common adverse effect.

This review discusses the use of 5α-reductase inhibitors in treating benign prostatic hyperplasia, highlighting their long-term effectiveness and benefits when combined with α1-adrenergic antagonists; it reports no new clinical results.

Combination therapy of doxazosin and finasteride safely and effectively reduces benign prostatic hyperplasia progression risk.

Finasteride, a hair loss drug, can cause sexual side effects like erectile dysfunction in 2.1%-3.8% of users, but these usually go away with time or if the drug is stopped. Despite this, its impact on sexual function is minimal for most men.

This study concluded that domestic and imported finasteride tablets are bioequivalent, with no significant differences in their pharmacokinetics among healthy volunteers.

In this study using a rat model, discontinuing dutasteride improved some relaxant responses but did not fully restore erectile function, indicating a potential time-dependent detriment of the drug.